← Back to Analyst Consensus 
CLOV Buy
CLOVER HEALTH INVESTMENTS, CORP. /DE
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 6, 2026 | UBS | maintain | Neutral → Neutral | — | 54% |
| Jul 21, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 11, 2026 | UBS | maintain | Neutral → Neutral | — | 54% |
| Jun 4, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 20, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 5, 2026 | Leerink Partners | maintain | Market Perform → Market Perform | — | 51% |
| Jan 20, 2026 | Canaccord Genuity | maintain | Buy → Buy | $3.7 | 48% |
| Nov 6, 2025 | Canaccord Genuity | maintain | Buy → Buy | $3.7 | 48% |
| Aug 7, 2025 | Canaccord Genuity | maintain | Buy → Buy | $4.1 | 48% |
| Aug 6, 2025 | UBS | maintain | Neutral → Neutral | $3 | 54% |
| Mar 3, 2025 | Canaccord Genuity | maintain | Buy → Buy | $4.5 | 48% |
| Dec 17, 2024 | Craig-Hallum | initiate | — → Buy | $6 | 54% |
| Oct 7, 2024 | UBS | initiate | — → Neutral | $4 | 54% |
| Aug 11, 2023 | Citigroup | maintain | Neutral → Neutral | $1.5 | 54% |
| Mar 6, 2023 | Canaccord Genuity | maintain | — → Buy | $3 | 48% |
| Mar 6, 2023 | Credit Suisse | maintain | — → Underperform | $1.25 | — |
| Nov 16, 2022 | Citigroup | maintain | — → Neutral | $1.8 | 54% |
| Nov 8, 2022 | SVB Leerink | maintain | — → Market Perform | $1.5 | — |
| Aug 9, 2022 | Citigroup | maintain | — → Neutral | $3.5 | 54% |
| Aug 9, 2022 | Credit Suisse | maintain | — → Underperform | $3 | — |
| May 10, 2022 | SVB Leerink | maintain | — → Market Perform | $3 | — |
| Feb 25, 2022 | SVB Leerink | maintain | — → Market Perform | $2.5 | — |
| Feb 2, 2022 | Canaccord Genuity | initiate | — → Buy | $6 | 48% |
| Feb 2, 2022 | Cowen & Co. | upgrade | Underperform → Market Perform | $3 | — |
| Jan 19, 2022 | SVB Leerink | initiate | — → Market Perform | $3 | — |
| Jan 7, 2022 | Credit Suisse | downgrade | Neutral → Underperform | $3.5 | — |
| Nov 15, 2021 | Credit Suisse | maintain | — → Neutral | $9 | — |
| Sep 10, 2021 | Cowen & Co. | initiate | — → Underperform | $7 | — |
| Jul 12, 2021 | JP Morgan | downgrade | Neutral → Underweight | $9 | 55% |
| Jun 10, 2021 | B of A Securities | downgrade | Neutral → Underperform | $10 | 53% |
| May 19, 2021 | Credit Suisse | maintain | — → Neutral | $9 | — |
| May 17, 2021 | B of A Securities | downgrade | Buy → Neutral | $9 | 53% |
| Mar 9, 2021 | Credit Suisse | initiate | — → Neutral | $10 | — |
| Feb 2, 2021 | Citigroup | initiate | — → Buy | $19 | 54% |
| Feb 1, 2021 | JP Morgan | initiate | — → Neutral | $15 | 55% |
Price Target Trend
Jun 25, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days